IMMUNOME INC.

• IMMUNOME INC.
• Health-Care

IMNM

We are a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Our proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. B cells are key elements in the human immune system response because they produce specific, high-affinity antibodies that bind to pathogens or cancer cells and target them for destruction by other immune effector cells.

Our platform is differentiated from those of other biotechnology companies because of our unbiased, broad, deep and efficient approach to identifying novel antibody-target pairs that may be useful in treating cancer and infectious diseases. Unlike other approaches that use deep sequencing of B cells to identify dominant clones that are common within and across patients, and which assume those clones are therapeutically relevant, we do not assume that any such genomic dominance is necessarily the hallmark of therapeutic utility. Instead, we typically capture thousands of individual memory B cells, immortalize them into large, stable hybridoma libraries, and then screen all of those individual antibodies for functional activity against complex cancer antigen sources, such as intact tumor cells and extracts of authentic human tumor material deposited on protein microarrays, to identify the specific antigen target of each antibody. We then use multiple functional assays, which allow us to to rationalize each antibody-target pair as a potential therapeutic approach. We are not aware of any other approach that interrogates the human B cell response to cancer in such an unbiased, deep and broad manner.

To date, we have processed more than 150 cancer patient memory B cell samples and have generated and screened more than 250,000 hybridomas, or stable, immortalized forms of B cell clones that produce a single antibody for extended periods of time. We have so far successfully identified approximately 1,200 individual antibodies, which we refer to as hits, that appear to bind to either a cancer cell or a tumor extract with high-affinity and specificity.

Using this approach, we have identified 50 potentially novel cancer targets. We believe that several of these antibody-target pairs could potentially form the basis of a therapeutic intervention or a diagnostic to detect such targets in a broader patient population. One of these unique targets is interleukin-38, or IL-38, a novel immune checkpoint inhibitor, which is the current focus of our lead discovery program, IMM-ONC-01. Upon successful completion of our preclinical evaluation, we expect to file an investigational new drug, or IND, application with the U.S. Food & Drug Administration, or FDA, in connection with this program in the second half of 2021. 

Offering Team

Pre-IPO Investors

Deal Highlights

less

More

Deal Tracker

Stock Price